Strong consortium of investors
The Seed round was closed with investment from a team of investors each bringing strategic, commercial and geographical benefits to the company. Led by Singapore-based Circulate Capital, the round also brought strategic investment from Coca-Cola Europacific Partners (CCEP), as well as UK-based impact investors Archipelago Ventures and the Circular Plastics Accelerator, an investment strategy built by climate NGO WRAP and managed by Archipelago Ventures. Pre-Seed investors TSP Ventures, a UK-based early-stage environmental technology investor, followed their investment having provided Nova's pre-seed funding in late 2023, providing further validation of the approach.
This investment is further reinforced by a €7.5M EU grant from CBE JU to accelerate product development in speciality chemicals, sustainable aviation fuel components, rubber components and coatings with strong industry support from multibillion companies like Solvay/Syensqo, UPM, Hansen & Rosenthal and Soprema.
Wolfgang Hafenmayer, Founding Partner of Circulate Capital, said, “Bio-based PET remains unavailable at commercial scale despite strong demand from industry. Nova’s technology has the dual potential for significant environmental impact and strong commercial returns, offering lower-carbon, renewable feedstocks that can help decarbonise the packaging and pulp and paper sectors while meeting real market demand.”
Lucy Mortimer, Founding Partner at Archipelago Ventures, said, “Nova Biochem offers an exciting pathway to decarbonisation of deeply embedded scope 3 emissions, at scale, whilst using a by-product of an existing sector which is itself seeking solutions to remove barriers to scale. We’re excited about the opportunities it offers, not least of which is the ability to geo-locate manufacturing of bio-based BTX and support resilience of regional and local supply chains.”
Pete Hodgson, Director, Coca-Cola Europacific Partners, said, “Our belief in innovation – and its role in delivering both sustainable progress and performance – is the driving force behind this investment. We’re delighted to welcome Alex and the team at Nova Biochem as our latest Ventures partners.”
Mike Doswell, Chief Investment Officer of TSP Ventures, said: "We are delighted to be following our pre-seed investment into Nova at this incredibly exciting phase of the company's development. Since backing Alex, Emre, and Sergey at a very early stage, the rate of technical and commercial progress has been truly impressive. Now, with this funding round secured, the European grant-funded project and a fantastic investor-base, the pathway to commercialisation and deployment of this transformative technology is clear".